Ascendis Pharma A/S Ordinary Share (ASND) is a publicly traded Healthcare sector company. As of July 26, 2026, ASND trades at $253.86 with a market cap of $16.65B and a P/E ratio of 0.00. ASND moved +0.50% today. Year to date, ASND is +19.05%; over the trailing twelve months it is +50.83%. Its 52-week range spans $118.03 to $282.15. Analyst consensus is strong buy with an average price target of $310.31. Rallies surfaces ASND's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Ascendis Reveals Week 104 Alignment and 52-Week Data in Achondroplasia Trials: Ascendis Pharma will present Week 104 ApproaCH Trial data showing improved lower-extremity alignment in achondroplasia children and 52-week radiographic and anthropometric results from the COACH combination therapy trial at ICCBH 2026. TransCon CNP gained FDA approval in February and is under EMA review while TransCon hGH remains investigational in achondroplasia.
| Metric | Value |
|---|---|
| Price | $253.86 |
| Market Cap | $16.65B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $282.15 |
| 52-Week Low | $118.03 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
14 analysts cover ASND: 0 strong buy, 14 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $310.31.